| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD300LB |
| Uniprot No | A8K4G0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-151aa |
| 氨基酸序列 | MWLPPALLLL SLSGCFSIQG PESVRAPEQG SLTVQCHYKQ GWETYIKWWC RGVRWDTCKI LIETRGSEQG EKSDRVSIKD NQKDRTFTVT MEGLRRDDAD VYWCGIERRG PDLGTQVKVI VDPEGAASTT ASSPTNSNMA VFIGSHKRNH Y |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于CD300LB相关研究方向的假设性参考文献示例(请注意，具体文献需通过学术数据库核实)：
1. **《CD300LB regulates HSV-1 infection by modulating type I IFN response》**
- 作者：Smith A, et al.
- 摘要：研究CD300LB重组蛋白在单纯疱疹病毒(HSV-1)感染中的作用，发现其通过增强I型干扰素通路抑制病毒复制，提示其免疫调节功能。
2. **《Structural characterization of CD300LB and its interaction with phosphatidylserine》**
- 作者：Li X, et al.
- 摘要：解析CD300LB重组蛋白的晶体结构，揭示其与磷脂酰丝氨酸(PS)结合的关键结构域，为靶向免疫检查点提供分子基础。
3. **《CD300LB as a co-receptor for hepatitis C virus entry in hepatocytes》**
- 作者：Tanaka R, et al.
- 摘要：发现CD300LB重组蛋白与HCV进入肝细胞相关，可能通过介导病毒与宿主膜融合促进感染，为抗病毒治疗提供新靶点。
4. **《CD300LB promotes neutrophil migration in bacterial sepsis》**
- 作者：Wang Y, et al.
- 摘要：利用CD300LB重组蛋白研究其在脓毒症中的作用，证明其通过激活Syk信号通路增强中性粒细胞迁移和杀菌能力。
---
**说明**：以上内容为假设性示例，实际文献需通过 **PubMed、Web of Science 或 Google Scholar** 等平台，以关键词“CD300LB recombinant protein”或“CD300LB function”检索。建议结合具体研究方向(如病毒感染、免疫调控等)筛选文献。
CD300LB, also known as CLM-7 or LMIR5. is a transmembrane glycoprotein belonging to the CD300 family of immune regulatory receptors. Expressed primarily on myeloid cells (e.g., neutrophils, monocytes, dendritic cells) and some lymphoid subsets, it regulates immune responses by interacting with lipid ligands such as phosphatidylserine (PS) and phosphatidylethanolamine exposed on stressed/apoptotic cells or pathogens. Structurally, it contains an extracellular immunoglobulin (Ig)-like V-type domain, a transmembrane region, and a cytoplasmic tail with signaling motifs. CD300LB functions as both an activating and inhibitory receptor, depending on its association with adaptor proteins (e.g., DAP12 for activating signals).
Recombinant CD300LB protein is engineered to study its ligand interactions, signaling mechanisms, and therapeutic potential. Produced via heterologous expression systems (e.g., mammalian cells, E. coli), it typically includes the extracellular domain to preserve ligand-binding activity. Purification techniques like affinity chromatography ensure high purity for functional assays. Research applications include elucidating its role in infections, inflammation, and cancer. For example, CD300LB recognizes PS on enveloped viruses (e.g., influenza) or apoptotic cells, modulating phagocytosis and cytokine release. It also influences neutrophil migration in sepsis and tumor microenvironment interactions.
Current studies focus on CD300LB as a biomarker or immunotherapeutic target. Recombinant proteins enable antibody development, ligand screening, and structural studies (e.g., crystallography), advancing understanding of its dual regulatory roles in immune homeostasis and disease.
×
